{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:18:44Z","timestamp":1783207124356,"version":"3.54.6"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Investigator-initiated (research) grant from Pfizer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"DOI":"10.1186\/s41479-026-00203-4","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:01:37Z","timestamp":1783206097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic non-susceptibility associated serotypes of invasive pneumococcal disease - a nationwide population study from Switzerland, 2012\u20132022"],"prefix":"10.1186","volume":"18","author":[{"given":"Nicolaj","family":"Just","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Baty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner C.","family":"Albrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hilty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"key":"203_CR1","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3201\/eid2808.212469","volume":"28","author":"KA Versluys","year":"2022","unstructured":"Versluys KA, Eurich DT, Marrie TJ, Tyrrell GJ. Invasive Pneumococcal Disease and Long-Term Mortality Rates in Adults, Alberta, Canada. Emerg Infect Dis. 2022;28:1615\u201323.","journal-title":"Emerg Infect Dis"},{"key":"203_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.vaccine.2015.11.048","volume":"34","author":"GH Wagenvoort","year":"2016","unstructured":"Wagenvoort GH, Knol MJ, de Melker HE, Vlaminckx BJ, van der Ende A, Rozenbaum MH, Sanders EA. Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands. Vaccine. 2016;34:334\u201340.","journal-title":"Vaccine"},{"key":"203_CR3","doi-asserted-by":"publisher","first-page":"e0017524","DOI":"10.1128\/cmr.00175-24","volume":"38","author":"FA Ganaie","year":"2025","unstructured":"Ganaie FA, Beall BW, Yu J, van der Linden M, McGee L, Satzke C, Manna S, Lo SW, Bentley SD, Ravenscroft N, Nahm MH. Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward. Clin Microbiol Rev. 2025;38:e0017524.","journal-title":"Clin Microbiol Rev"},{"key":"203_CR4","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","volume":"5","author":"D Shaw","year":"2023","unstructured":"Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, Cao B, Casanova C, Choi EH, Chu YW, et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5:e582\u201393.","journal-title":"Lancet Digit Health"},{"key":"203_CR5","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"AB Brueggemann","year":"2021","unstructured":"Brueggemann AB, van Jansen MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, van der Linden MPG, Amin-Chowdhury Z, Bennett DE, Borrow R, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3:e360\u201370.","journal-title":"Lancet Digit Health"},{"key":"203_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","volume":"25","author":"M Garcia Quesada","year":"2025","unstructured":"Garcia Quesada M, Peterson ME, Bennett JC, Hayford K, Zeger SL, Yang Y, Hetrich MK, Feikin DR, Cohen AL, von Gottberg A, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025;25:445\u201356.","journal-title":"Lancet Infect Dis"},{"key":"203_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1473-3099(24)00665-0","volume":"25","author":"JC Bennett","year":"2025","unstructured":"Bennett JC, Deloria Knoll M, Kagucia EW, Garcia Quesada M, Zeger SL, Hetrich MK, Yang Y, Herbert C, Ogyu A, Cohen AL, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025;25:457\u201370.","journal-title":"Lancet Infect Dis"},{"key":"203_CR8","doi-asserted-by":"crossref","unstructured":"King LM, Andrejko KL, Kobayashi M, Xing W, Cohen AL, Lewnard JA. Acute respiratory infections due to antibiotic-nonsusceptible Streptococcus pneumoniae in United States adults. medRxiv. 2025.","DOI":"10.1101\/2025.04.04.25325277"},{"key":"203_CR9","first-page":"656","volume":"48","author":"C Centers for Disease","year":"1999","unstructured":"Centers for Disease C, Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae\u2013selected sites, United States, 1997. MMWR Morb Mortal Wkly Rep. 1999;48:656\u201361.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"203_CR10","doi-asserted-by":"publisher","first-page":"1337276","DOI":"10.3389\/fpubh.2024.1337276","volume":"12","author":"MM Sandoval","year":"2024","unstructured":"Sandoval MM, Ruvinsky S, Palermo MC, Alconada T, Brizuela ME, Wierzbicki ER, Cantos J, Bardach A, Ciapponi A, Gagetti P. Antimicrobial resistance of Streptococcus pneumoniae from invasive pneumococcal diseases in Latin American countries: a systematic review and meta-analysis. Front Public Health. 2024;12:1337276.","journal-title":"Front Public Health"},{"key":"203_CR11","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1056\/NEJM200012283432603","volume":"343","author":"CG Whitney","year":"2000","unstructured":"Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917\u201324.","journal-title":"N Engl J Med"},{"key":"203_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nm839","volume":"9","author":"AW McCormick","year":"2003","unstructured":"McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med. 2003;9:424\u201330.","journal-title":"Nat Med"},{"key":"203_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2807\/1560-7917.ES.2016.21.21.30239","volume":"21","author":"C Hauser","year":"2016","unstructured":"Hauser C, Kronenberg A, Allemann A, Muhlemann K, Hilty M. Serotype\/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. Eurosurveillance. 2016;21:12\u201321.","journal-title":"Eurosurveillance"},{"key":"203_CR14","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1016\/j.vaccine.2014.07.060","volume":"32","author":"J Meichtry","year":"2014","unstructured":"Meichtry J, Born R, Kuffer M, Zwahlen M, Albrich WC, Brugger SD, Muhlemann K, Hilty M. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: A nationwide population-based study. Vaccine. 2014;32:5185\u201391.","journal-title":"Vaccine"},{"key":"203_CR15","doi-asserted-by":"crossref","unstructured":"Oyewole OR, Lang P, Albrich WC, Wissel K, Leib SL, Casanova C, Hilty M. The impact of pneumococcal conjugate vaccine (PCV) coverage heterogeneities on the changing epidemiology of invasive pneumococcal disease in Switzerland, 2005\u20132019. Microorganisms 2021, 9.","DOI":"10.3390\/microorganisms9051078"},{"key":"203_CR16","doi-asserted-by":"publisher","first-page":"759602","DOI":"10.3389\/fpubh.2021.759602","volume":"9","author":"KD Zens","year":"2021","unstructured":"Zens KD, Baroutsou V, Fehr JS, Lang P. Pneumococcal Vaccination Coverage and Uptake Among Adults in Switzerland: A Nationwide Cross-Sectional Study of Vaccination Records. Front Public Health. 2021;9:759602.","journal-title":"Front Public Health"},{"key":"203_CR17","doi-asserted-by":"crossref","unstructured":"Kovacevic A, Smith DRM, Rahbe E, Novelli S, Henriot P, Varon E, Cohen R, Levy C, Temime L, Opatowski L. Exploring factors shaping antibiotic resistance patterns in Streptococcus pneumoniae during the 2020 COVID-19 pandemic. Elife 2024, 13.","DOI":"10.7554\/eLife.85701"},{"key":"203_CR18","doi-asserted-by":"publisher","first-page":"2488189","DOI":"10.1080\/22221751.2025.2488189","volume":"14","author":"WC Albrich","year":"2025","unstructured":"Albrich WC, Just N, Kahlert C, Casanova C, Baty F, Hilty M. Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012\u20132022. Emerg Microbes Infect. 2025;14:2488189.","journal-title":"Emerg Microbes Infect"},{"key":"203_CR19","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.lanmic.2025.101102","volume":"6","author":"JC D\u2019Aeth","year":"2025","unstructured":"D\u2019Aeth JC, Bertran M, Abdullahi F, Eletu S, Hani E, Fry NK, Ladhani SN, Litt DJ. Whole-genome sequencing, strain composition, and predicted antimicrobial resistance of Streptococcus pneumoniae causing invasive disease in England in 2017-20: a prospective national surveillance study. Lancet Microbe. 2025;6:101102.","journal-title":"Lancet Microbe"},{"key":"203_CR20","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S2666-5247(21)00064-1","volume":"2","author":"K Andrejko","year":"2021","unstructured":"Andrejko K, Ratnasiri B, Hausdorff WP, Laxminarayan R, Lewnard JA. Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. Lancet Microbe. 2021;2:e450\u201360.","journal-title":"Lancet Microbe"},{"key":"203_CR21","doi-asserted-by":"crossref","unstructured":"Raemy S, Casanova C, Baldan R, Barreto E, Tande AJ, Endimiani A, Leib SL, Fischer U, Sendi P. Penicillin-susceptible Streptococcus pneumoniae meningitis in adults: does the ceftriaxone dosing matter? Antibiot (Basel) 2023;12.","DOI":"10.3390\/antibiotics12050878"},{"key":"203_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S0950268801006331","volume":"128","author":"MH Kyaw","year":"2002","unstructured":"Kyaw MH, Clarke S, Jones IG, Campbell H. Non-invasive pneumococcal disease and antimicrobial resistance: vaccine implications. Epidemiol Infect. 2002;128:21\u20137.","journal-title":"Epidemiol Infect"},{"key":"203_CR23","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1073\/pnas.1718712115","volume":"115","author":"U Obolski","year":"2018","unstructured":"Obolski U, Lourenco J, Thompson C, Thompson R, Gori A, Gupta S. Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae. Proc Natl Acad Sci USA. 2018;115:3102\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"203_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/cid\/ciw067","volume":"62","author":"S Tomczyk","year":"2016","unstructured":"Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, Holtzman C, Zansky SM, Thomas A, Baumbach J, et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis. 2016;62:1119\u201325.","journal-title":"Clin Infect Dis"},{"key":"203_CR25","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/cid\/cix446","volume":"65","author":"MR Schroeder","year":"2017","unstructured":"Schroeder MR, Chancey ST, Thomas S, Kuo WH, Satola SW, Farley MM, Stephens DS. A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms. Clin Infect Dis. 2017;65:990\u20138.","journal-title":"Clin Infect Dis"},{"key":"203_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/cid\/ciaa157","volume":"72","author":"R Kaur","year":"2021","unstructured":"Kaur R, Pham M, Yu KOA, Pichichero ME. Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. Clin Infect Dis. 2021;72:797\u2013805.","journal-title":"Clin Infect Dis"},{"key":"203_CR27","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/jac\/dkaf253","volume":"80","author":"C Horner","year":"2025","unstructured":"Horner C, Reynolds R, Mushtaq S, Chaudhry A, Adkin R, Allen M, Longshaw C, Parcell BJ, Livermore DM. Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999\u20132019). J Antimicrob Chemother. 2025;80:iv72\u201386.","journal-title":"J Antimicrob Chemother"},{"key":"203_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/cid\/ciab852","volume":"75","author":"K Andrejko","year":"2022","unstructured":"Andrejko K, Ratnasiri B, Lewnard JA. Association of Pneumococcal Serotype With Susceptibility to Antimicrobial Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis. 2022;75:131\u201340.","journal-title":"Clin Infect Dis"},{"key":"203_CR29","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/S2666-5247(22)00158-6","volume":"3","author":"SW Lo","year":"2022","unstructured":"Lo SW, Mellor K, Cohen R, Alonso AR, Belman S, Kumar N, Hawkins PA, Gladstone RA, von Gottberg A, Veeraraghavan B, et al. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe. 2022;3:e735\u201343.","journal-title":"Lancet Microbe"},{"key":"203_CR30","doi-asserted-by":"publisher","first-page":"e0169624","DOI":"10.1128\/jcm.01696-24","volume":"63","author":"L Dierckx","year":"2025","unstructured":"Dierckx L, Rodriguez-Ruiz JP, Ekinci E, van Heirstraeten L, Willen L, Cuypers L, Beutels P, Maertens K, Desmet S, Theeten H, Malhotra-Kumar S. Pneumococcal genotype 23B1 as a driver of increased 23B serotype carriage, penicillin non-susceptibility, and invasive disease in Belgium: a retrospective analysis. J Clin Microbiol. 2025;63:e0169624.","journal-title":"J Clin Microbiol"},{"key":"203_CR31","doi-asserted-by":"publisher","first-page":"101513","DOI":"10.1016\/j.nmni.2024.101513","volume":"62","author":"M Kawaguchiya","year":"2024","unstructured":"Kawaguchiya M, Urushibara N, Aung MS, Ohashi N, Tsutida S, Kurashita K, Ito M, Kobayashi N. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolated from children in Japan, 2023. New Microbes New Infect. 2024;62:101513.","journal-title":"New Microbes New Infect"},{"key":"203_CR32","doi-asserted-by":"publisher","first-page":"e1470","DOI":"10.1016\/S2214-109X(24)00263-8","volume":"12","author":"A von Gottberg","year":"2024","unstructured":"von Gottberg A, Kleynhans J, de Gouveia L, Tempia S, Meiring S, Quan V, du Plessis M, von Mollendorf C, Crowther-Gibson P, Avenant T, et al. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study. Lancet Glob Health. 2024;12:e1470\u201384.","journal-title":"Lancet Glob Health"},{"key":"203_CR33","doi-asserted-by":"publisher","first-page":"e0153025","DOI":"10.1128\/aac.01530-25","volume":"70","author":"J Llorente","year":"2026","unstructured":"Llorente J, Sempere J, Llamosi M, Perez-Garcia C, Ubeda A, Vidal-Alcantara EJ, Sanz JC, Domenech M, Yuste J. Emergence of antibiotic-resistant pneumococcal serotypes causing invasive pneumococcal disease in children, Spain. Antimicrob Agents Chemother. 2026;70:e0153025.","journal-title":"Antimicrob Agents Chemother"},{"key":"203_CR34","doi-asserted-by":"crossref","unstructured":"Vermeulen H, Cuypers L, Catry B, Desmet S, Hens N. Higher valency vaccines\u2019 impact on antimicrobial resistance rates in Streptococcus pneumoniae causing invasive disease: a retrospective analysis based on national reference laboratory data, Belgium, 2018 to 2023. Euro Surveill 2025, 30.","DOI":"10.2807\/1560-7917.ES.2025.30.45.2500179"},{"key":"203_CR35","doi-asserted-by":"crossref","unstructured":"Teixeira R, Kossyvaki V, Galvez P, Mendez C. Pneumococcal serotype evolution and burden in european adults in the last decade: a systematic review. Microorganisms 2023;11.","DOI":"10.3390\/microorganisms11061376"},{"key":"203_CR36","doi-asserted-by":"publisher","first-page":"127138","DOI":"10.1016\/j.vaccine.2025.127138","volume":"54","author":"N Takeuchi","year":"2025","unstructured":"Takeuchi N, Chang B, Ishiwada N, Cho Y, Nishi J, Okada K, Fujieda M, Oda M, Saitoh A, Hosoya M, et al. Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014\u20132022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic. Vaccine. 2025;54:127138.","journal-title":"Vaccine"},{"key":"203_CR37","first-page":"101113","volume":"46","author":"J Zintgraff","year":"2025","unstructured":"Zintgraff J, Gagetti P, Eluchans NS, Marchetti P, Moscoloni MA, Irazu L, Lara CS, Argentina Spn Working G, Corso A. Invasive pneumococcal disease in Argentina: a snapshot from a retrospective observational study on serotypes, antimicrobial resistance, and the potential impact of the COVID-19 pandemic (2018\u20132022). Lancet Reg Health Am. 2025;46:101113.","journal-title":"Lancet Reg Health Am"},{"key":"203_CR38","doi-asserted-by":"publisher","first-page":"106519","DOI":"10.1016\/j.jinf.2025.106519","volume":"91","author":"K Hajji","year":"2025","unstructured":"Hajji K, Wrobel-Pawelczyk I, van Veldhuizen J, Maruhn K, Miellet WR, Mariman R, Steens A, van Sorge NM, Trzcinski K, van der Linden MPG, et al. Streptococcus pneumoniae serotype 38 emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands. J Infect. 2025;91:106519.","journal-title":"J Infect"},{"key":"203_CR39","doi-asserted-by":"publisher","first-page":"104632","DOI":"10.1016\/j.idnow.2022.11.001","volume":"53","author":"C Plainvert","year":"2023","unstructured":"Plainvert C, Varon E, Viriot D, Kempf M. French Regional Pneumococcal Observatories n: Invasive pneumococcal infections in France: Changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network. Infect Dis Now. 2023;53:104632.","journal-title":"Infect Dis Now"},{"key":"203_CR40","doi-asserted-by":"publisher","first-page":"103145","DOI":"10.1016\/j.jiph.2026.103145","volume":"19","author":"I Amoruso","year":"2026","unstructured":"Amoruso I, Fonzo M, Agostini S, Russo F, Baldo V, Baldovin T, Bertoncello C. Trends in Streptococcus pneumoniae serotypes and antimicrobial resistance in Italy (2007\u20132023): A mixed-effects model analysis of invasive pneumococcal disease. J Infect Public Health. 2026;19:103145.","journal-title":"J Infect Public Health"},{"key":"203_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","volume":"16","author":"E Backhaus","year":"2016","unstructured":"Backhaus E, Berg S, Andersson R, Ockborn G, Malmstrom P, Dahl M, Nasic S, Trollfors B. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16:367.","journal-title":"BMC Infect Dis"},{"key":"203_CR42","doi-asserted-by":"publisher","first-page":"11865","DOI":"10.1038\/s41598-021-91234-y","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, Matsumoto H, Horita N, Hara Y, Kobayashi N, Kaneko T. Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep. 2021;11:11865.","journal-title":"Sci Rep"},{"key":"203_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/thoraxjnl-2012-203106","volume":"68","author":"P Naucler","year":"2013","unstructured":"Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax. 2013;68:571\u20139.","journal-title":"Thorax"},{"key":"203_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1473-3099(18)30349-9","volume":"18","author":"N Ouldali","year":"2018","unstructured":"Ouldali N, Levy C, Varon E, Bonacorsi S, Bechet S, Cohen R, Angoulvant F, French Pediatric Meningitis N. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect Dis. 2018;18:983\u201391.","journal-title":"Lancet Infect Dis"},{"key":"203_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.vaccine.2021.12.008","volume":"40","author":"J Zintgraff","year":"2022","unstructured":"Zintgraff J, Gagetti P, Napoli D, Sanchez Eluchans N, Irazu L, Moscoloni M, Argentina Spn Working G, Regueira M, Lara CS, Corso A. Invasive Streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006\u20132019. Temporal progression of serotypes distribution and antibiotic resistance. Vaccine. 2022;40:459\u201370.","journal-title":"Vaccine"},{"key":"203_CR46","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.cmi.2025.03.019","volume":"31","author":"A Petropoulos","year":"2025","unstructured":"Petropoulos A, Morfeldt E, Nyren K, Blomqvist K, Henriques-Normark B. Broth microdilution susceptibility testing reveals underestimation of resistance to penicillin and high levels of resistance to ampicillin of Streptococcus pneumoniae clinical isolates in Sweden. Clin Microbiol Infect. 2025;31:1225\u20137.","journal-title":"Clin Microbiol Infect"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-026-00203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-026-00203-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-026-00203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:01:58Z","timestamp":1783206118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41479-026-00203-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1186\/s41479-026-00203-4","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,5]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis uses de-identified public health surveillance data collected under the epidemics act and does not require approval by an ethics board, in accordance with the Federal Act on Research involving Human Beings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WCA has received travel grants (Pfizer, Gilead) and reimbursement for advisory boards (Pfizer, MSD, Sanofi-Aventis, GSK, OM Pharma, Janssen, Moderna) or presentations (Pfizer, MSD, GSK, Gilead), paid to his institution. MH received reimbursement for advisory boards (Pfizer and MSD) or presentations (Pfizer, and MSD).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}